China Companion Animal Health market Share, Regional Outlook, Survey Report 2028

China Companion Animal Health Industry Overview

The China companion animal health market size was valued at USD 962.8 million in 2020 and is estimated to grow at a compound annual growth rate (CAGR) of 11.3% from 2021 to 2028.

The growing companion animal population, pet humanization, incidence of diseases in animals, and initiatives by key companies are the key factors driving the market growth in the country. In May 2021, Boehringer Ingelheim, for example, received approval for GastroGard, intended for horses, from the Ministry of Agriculture and Rural Affairs of China. With this, Boehringer Ingelheim became the first global animal health company with equine business in China. The COVID-19 pandemic had a mixed impact on the market. The negative effects resulting from movement restrictions and logistical hurdles resulted in low demand and sales for certain market players.

Gather more insights about the market drivers, restrains and growth of the China Companion Animal Health Market

China companion animal medicine market size, by animal type, 2018 - 2028 (USD Million)

Some global MNCs redirected their resources to lower lucrative segments and opportunities. During the third quarter of 2020, Zoetis reported that favorable market conditions along with its promotional and educational efforts resulted in increased sales of companion animal products in China. The country also witnessed rising pet ownership. This is estimated to fuel demand for pet medicines and diagnostic products in the coming years. Chinese pet parents spend about USD 784.18 annually on their pets, and this trend was anticipated to increase over time. This factor combined with the growing initiatives by market players is expected to propel the market growth.

According to Virbac, there was almost no local competition in the companion animal segment in China in 2016, making it an ideal market for the company to expand into. As part of its growth strategy, Virbac focused on spearheading a direct distribution model to vet clinics in China. The competition has increased over time with the entry of other international livestock medicine companies diversifying into the pet medicine segment and the introduction of generics by local companies. However, there are opportunities in the market due to the growing demand for treatment options for pets and increasing pet expenditure.

In addition, infectious diseases caused by virulent pathogens may seriously affect the animal’s way of life and lifespan. The demand for various preventive treatment options, such as vaccines and pharmaceuticals, is anticipated to increase with the growing pet health awareness. Many veterinarians and clinicians recommend screening pets for infectious diseases annually. This can enable timely detection of communicable diseases, ensure treatment, and may also contribute to the prevention of complex cases. The growing incidence of zoonoses, pet health concerns, and product developments by market players are expected to fuel the segment growth. In April 2017, Zoetis launched the Witness Lepto point-of-care test to detect acute leptospirosis in dogs.

Browse through Grand View Research’s Animal Health Industry Research Reports.

  • Bovine Tuberculosis Diagnosis Market: The global bovine tuberculosis diagnosis market size was valued at USD 707.4 million in 2021 and is estimated to expand at a compound annual growth rate (CAGR) of 4.2% from 2022 to 2030.
  • South Africa Veterinary Medicine Market: The South African veterinary medicine market size was valued at USD 116.96 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 10.1% from 2021 to 2028.

Market Share Insights

  • March 2021: Boehringer Ingelheim launched Shengmila, an imported original drug, in China for the treatment of chronic kidney disease in cats.
  • June 2020: The World Bank Group approved a loan of USD 300 million to help strengthen select national and provincial systems in China to lower the risk of zoonoses and other emerging health threats as part of the Emerging Infectious Diseases Prevention, Preparedness and Response Project.
  • February 2019: Boehringer Ingelheim, for instance, launched the first-of-its-kind flagship store by a multinational animal health company on Tmall for pet parasiticides. The store was launched to provide customers with a reliable and convenient online purchasing channel for the company’s full range of pet parasiticides.

Key Companies profiled:

Some of the prominent players in the China companion animal health market include:

  • Boehringer Ingelheim International GmbH
  • Elanco
  • Merck & Co., Inc.
  • Zoetis
  • Ceva
  • Virbac
  • Bimeda, Inc.
  • IDEXX Laboratories
  • Thermo Fisher Scientific
  • Randox Laboratories

Order a free sample PDF of the China Companion Animal Health Market Intelligence Study, published by Grand View Research.

Comments are closed